Search

Your search keyword '"Halabi, Majdi"' showing total 50 results

Search Constraints

Start Over You searched for: Author "Halabi, Majdi" Remove constraint Author: "Halabi, Majdi" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
50 results on '"Halabi, Majdi"'

Search Results

1. Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term Extension

4. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis

5. Absence of Pericarditis Recurrence in Rilonacept-Treated Patients with COVID-19 and SARS-CoV-2 Vaccination: Results from RHAPSODY Long-Term Extension

6. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

7. Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

8. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

9. Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.

10. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis

11. Impact of Multisite artery disease on Clinical Outcomes After Percutaneous Coronary Intervention : An Analysis from the e-Ultimaster Registry

13. Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY

16. Protective Effects of BNT162b2 Vaccination on Aerobic Capacity Following Mild to Moderate SARS-CoV-2 Infection: A Cross-Sectional Study Israel

19. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

20. Prognosis of PCI in AMI setting in the elderly population: Outcomes from the multicenter prospective e‐ULTIMASTER registry.

21. Transcatheter closure of ruptured right-coronary aortic sinus fistula to right ventricle

22. Acute myocardial infarction in the Covid-19 era: Incidence, clinical characteristics and in-hospital outcomes—A multicenter registry

25. Front Cover

28. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

29. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

30. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

31. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

32. MRI active guidewire with an embedded temperature probe and providing a distinct tip signal to enhance clinical safety

33. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

35. Torsades de pointes after prolonged intravenous amiodarone therapy for atrial fibrillation.

36. THE SAFETY AND TOLERABILITY OF MULTIPLE DOSE ADMINISTRATION OF CSL112, AN INTRAVENOUS FORMULATION OF PLASMA-DERIVED APOA-I, AMONG SUBJECTS WITH MODERATE RENAL IMPAIRMENT AFTER ACUTE MYOCARDIAL INFARCTION

37. Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.

41. Transthoracic delivery of large devices into the left ventricle through the right ventricle and interventricular septum: preclinical feasibility

42. Real-time MRI-guided right heart catheterization in adults using passive catheters

45. Stenting very small (<2 mm) coronary artery lesions

47. Stenting very small (

48. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

49. Moderately stenotic lesions: a question of stenting.

50. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.

Catalog

Books, media, physical & digital resources